Analysis and treatment of adverse reactions associated with four gadolinium contrast agents

doi:10.12092/j.issn.1009-2501.2018.09.015

Abstract

Abstract:

AIM: To discuss the factors related to the adverse reaction (ADR) in the clinical application of four gadolinium contrast agents and the best way to deal with it. METHODS: The characteristics of the contrast agent, the patient's constitution, the diagnosis and treatment, the application of contrast agent, the history of pre-enhanced basic medication and the occurrence of ADR (gadolinium contrast agent osmotic pressure, the form of the blood in the blood after the injection, the way of excretion, the patient's age, sex, dosage, injection, enhancement time, enhanced site; ADR reaction time, severity, treatment after treatment) were compared to comprehensively analyze the contrast agent adverse reaction factors, summary of contrast agent induced acute, late onset and ultra late onset ADR incidence, occurrence characteristics and corresponding clinical treatment methods. RESULTS: Age, injection velocity, pre- enhanced base medication and scanning site were independent risk factors for gadolinium contrast agent ADR; linear ionic specific agent had the highest ADR; the symptoms of various systems and different levels of ADR were strictly symptomatic; all the systems were most common with acute skin symptoms, without special treatment, high recovery rate, late onset or super. Late onset patients need to be treated with antihistamine or glucocorticoid, and no gadolinium deposits of NSF, dentate nucleus, double lung, and pleura were found in patients who had been enhanced with a number of large dose contrast agents within 4 years of follow-up. CONCLUSION: The relative incidence of ring-shaped contrast agents show less ADR, and the history of basic medication (diabetes, allergic rhinitis, tumor History) before the enhancement, and the middle-aged outpatient with large dose of slow weight and light weight when the enhancement is enhanced, have the highest acute mild ADR. The medical workers in the imaging department should master the reasonable ADR treatment, which can effectively reduce the incidence of adverse reactions.

Key words: gadolinium contrast medium, adverse drug reaction, NSF, MRI

CLC Number:

R817
R9

WANG Junda, LENG Jing, YANG yalin, LI Yanyan. Analysis and treatment of adverse reactions associated with four gadolinium contrast agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1056-1062.

References

［1］Aran S, Shaqdan KW, Abujudeh HH. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections［J］. Clin Radiol, 2015, 70(5):466-475.
［2］王军大, 李艳艳. 8例碘克沙醇静脉注射致不良反应报告分析［J］. 中国药业, 2016, 25(17):79-82.
［3］Heshmatzadeh BA, Prince MR. Preventing allergic reactions to gadolinium-based contrast agents ［J］. Top Magn Reson Imaging, 2016, 25(6):275-279.
［4］孙艳, 郭小超, 黄勇,等. MR钆对比剂全身性不良反应的研究:18540例连续病例分析［J］. 放射学实践, 2016, 31(12):1159-1162.
［5］Kim JA, Blumenfeld JD, Chhabra S, et al. Pancreatic cysts in autosomal dominant polycystic kidney disease: prevalence and association with PKD2 gene mutations［J］. Radiology, 2016, 280(3):762-770.
［6］Takahashi S, Takada A, Saito K, et al. Fatal anaphylaxis associated with the gadolinium-based contrast agent gadoteridol (ProHance).［J］. J Investigational Allergology & Clinical Immunology, 2015, 25(5):366-367.
［7］王军大, 冷静, 李艳艳. 7种静脉注射碘对比剂的合理应用及其不良反应分析［J］. 中国医院药学杂志, 2018,38(6):212-213.
［8］Donald RJ, Mc Donald JS, Kallmes DF,等. 对比增强MRI后颅内钆剂沉积［J］. 国际医学放射学杂志, 2015,38(4):141-144.
［9］Tepetam F M, Ciftaslan N, Oru, et al. Should patients with risk factors be tested for hypersensitivity to contrast media: a prospective study［J］. La Radiologia Medica, 2016, 121(8):660-666.
［10］Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms［J］. Biometals, 2016, 29(3):365-376.
［11］Costello JR, Kalb B, Martin DR. Incidence and risk factors for gadolinium-based contrast agent immediate reactions［J］. Top Magn Reson Imaging, 2016, 25(6):257-263.
［12］Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients［J］. Radiology, 2015, 275(3):630-634.
［13］Power S, Talbot N, Kucharczyk W,等. MRI对比剂钆布醇的过敏样反应:32991例连续注射病例的前瞻性研究［J］. 国际医学放射学杂志, 2016, 39(6) :163-166.
［14］林义秋, 李莉, 谭文慧. 钆喷酸葡胺对比剂在临床中的不良反应分析［J］. 解放军药学学报, 2015, 31(2):177-178.
［15］叶红梅, 李勇, 张丽群,等. 临床常用磁共振对比剂不良反应观察［J］. 临床合理用药杂志, 2014, 7(12):101-102.
［16］李信华. 47例钆喷酸葡胺注射液不良反应的文献分析［J］. 中南药学, 2016,14(3):333-335.
［17］周庆春. 189例磁共振对比剂钆喷酸普胺致不良反应病例的文献分析［J］. 抗感染药学, 2016, 13(1):118-120.
［18］Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent ［J］. Radiology, 2015, 275(3):783-791.
［19］Carr TF. Pathophysiology of immediate reactions to injectable gadolinium-based contrast agents［J］. Top Magn Reson Imaging, 2016, 25(6):265-268.
［20］Neeley C, Moritz M, Brown JJ, et al. Acute side effects of three commonly used gadolinium contrast agents in the pediatric population［J］. Br J Radiol, 2016:20160027.
［21］Rosado I A, Doa DI, Cabaas MR, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media.［J］. J Investig Allerg Clin Immunol, 2016, 26(3):144-155.
［22］Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium- 1997-2006-2016. Part 1［J］. Acta Radiologica, 2016, 57(5):515-520.
［23］陈杰, 元刚, 陈孝,等. 临床药师参与1例钆喷酸葡胺致抽搐、昏迷患者救治的药学实践［J］. 今日药学, 2014, 24(5):366-367.
［24］Granata V, Cascella M, Fusco R, et al. Immediate adverse reactions to gadolinium-based MR contrast media: A retrospective analysis on 10,608 examinations［J］. Biomed Res Int, 2016, 2016:1-6.
［25］左应琳, 刘丽, 李文华. 钆喷酸葡胺注射液致罕见过敏性休克1例［J］. 中南药学, 2013, 11(10):799-800.
［26］高志红, 刘丽华, 李杰,等. 一例钆喷酸葡胺注射液致过敏性休克的抢救及护理体会［J］. 临床合理用药杂志, 2015, 8(9):165-165.
［27］Beckett KR, Moriarity AK, Langer JM. Safe use of contrast media: what the radiologist needs to know［J］. Radiographics A Review Publication of the Radiological Society of North America Inc, 2015, 35(6):1738-1750.
［28］王军大, 沈怡, 李映. 钆喷酸葡胺对比剂行冠状动脉CTA诊断及临床安全性分析［J］. 现代医药卫生, 2014,30 (23):3600-3601.
［29］王洋, 纪立伟. 钆特酸葡胺注射液致过敏性休克［J］. 中国药物应用与监测, 2013, 10(5):305-306.

[1]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[2]	LIU Tong, XU Jiaming, WANG Jinhuo, YIN Lei, CHEN Yongquan, GUO Jianrong. Changes of anesthetic drug concentration in plasma during isolation of autologous blood with acute isovolumic hemodilution and its influence on anesthetic effect after reinfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 413-418.
[3]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[4]	NIU Pilian, FAN Yongxin, LU Furui, ZHOU Xuezhang, BAI Mingsheng. Effects of liquorice extract on cardiac fibroblasts fibrosis induced by TGF-β1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 129-135.
[5]	HE Liyang, WEI Wenjie, YIN Qin, LIU Lijing, ZHONG Boying, LIU Cungen, ZHOU Meiling, HE Jianbin. Preventive and therapeutic effects of the Kiwi fruit essence (unsaturated fatty acid of actinidia chinesis planch seed oil) on radiation-induced lung injury rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 154-162.
[6]	GUO Shengjie, GUAN Xirui, CAO Wenli, LIANG Sicheng, QI Xiaoyi, GE Guangbo, LV Muhan. Research progress on bile acid metabolism mediated by uridine diphosphate glucuronic acid transferase and its endogenous and exogenous influencing factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 102-107.
[7]	LIU Xin, LENG Yufang, ZHANG Xuehong, ZHANG Lili, ZHANG Mengjie, QU Shanshan, XIE Jianqin, WANG Yiqing. Application of nalbuphine in ultrasound-guided transvaginal oocyte retrieval and its effect on embryo quality and pregnancy outcome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1042-1047.
[8]	ZHOU Minmin, YU Lu, HAN Chao, GU Damin, LEI Daoyun. Relationship between human cholesteryl ester transfer protein rs5882 gene polymorphism and postoperative cognitive dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 768-774.
[9]	YIN Lei, XU Jiaming, WU Jingyi, DUAN Lishuang, WEI Hanwei, JIN Xiaoju, GUO Jianrong. Effect of acute normovolemic hemodilution autologous blood transfusion on the EEG bispectral index and muscle relaxation in elderly patients undergoing orthopedic surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1153-1158.
[10]	ZHAO Yuan, NIE Qianwen, YIN Jiangyan, HUAN Xuan, TIAN Meixiang, ZHANG Zhengyi. Research progress of dynamic regulation of lysine acetylation in heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1186-1192.
[11]	ZHOU Xiaohong, SHENG Yongjia, GU Yanling, WANG Jin. NADPH oxidase NOX4 inhibitor regulates the formation and mechanism of hepatoma related fibroblasts [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 976-983.
[12]	WEN Chunjie, ZHANG Ying, WU Lanxiang, ZHOU Honghao. Inhibitory effect of vemurafenib on UGT1A1-mediated irinotecan metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 773-777.
[13]	GU Yanling, SHENG Yongjia, WANG Jin. Polysaccharide inhibits tumor associated fibroblasts transformation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 266-271.
[14]	LI Yuqin, WANG Kai, AO Li, LU Xiaolan, SHI Jianping. miR-142-5p inhibits proliferation and migration of gastric cancer cells through DNMT1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1328-1334.
[15]	XU Shengsong, TAO Hui, SHI Kaihu, DING Jifei. Expression and clinical significance of EZH2 and α-SMA in myocardium of patients with rheumatic heart disease with atrial fibrillation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1371-1375.